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Polymeric-Based Perivascular Delivery
of a Nitric Oxide Donor Inhibits Intimal
Thickening After Balloon Denudation
Arterial Injury: Role of Nuclear Factor-kappaB
Sanjay Kaul, MD,*†‡ Bojan Cercek, MD, FACC,*†‡ Jan Rengstrom, MD, Xiao-Ping Xu, MD,*†‡
Mia D. Molloy, BS,*†‡ Paul Dimayuga, BS,*†‡ Akik K. Parikh, MD,*†‡ Michael C. Fishbein, MD,†‡
Jan Nilsson, MD, Tripathi B. Rajavashisth, PHD,*†‡ Prediman K. Shah, MD, FACC*†‡
Los Angeles, California and Stockholm, Sweden
OBJECTIVES To examine the effect of a polymeric-based periadventitial delivery of a nitric oxide
(NO)-releasing diazeniumdiolate, spermine/NO (SPER/NO), on balloon injury-induced
neointimal hyperplasia in rat ileofemoral arteries.
BACKGROUND Reduced local bioavailability and adverse side effects limit systemic administration of NO to
modulate vascular response to injury.
METHODS A polylactic-polyglycolic acid polymeric matrix containing 2.5% SPER/NO (w/w) was
applied around the injured arteries. Quantitative histomorphometry was performed at day 14,
proliferating cell nuclear antigen (PCNA) immunohistochemistry at day 3 to assess effects on
smooth muscle proliferation and electrophoretic mobility shift assay to evaluate effects on
transcription factor, nuclear factor-kappaB (NF-kappaB).
RESULTS Treatment with SPER/NO reduced the intimal area (0.011 6 0.009 vs. 0.035 6 0.006 mm2
control, p , 0.01) and the intima to media ratio (0.089 6 0.062 vs. 0.330 6 0.057 control,
p , 0.005). Spermine/nitric oxide produced a profound inhibition of PCNA-positive cells
(.75%, p , 0.005) and significantly suppressed the injury-induced activation of NF-kappaB.
Vascular cyclic guanosine monophosphate (cGMP) levels were elevated after treatment with
the SPER/NO (0.28 6 0.03 vs. 0.17 6 0.02 pmol/mg tissue control, p , 0.01). The
inhibitory effects on neointimal proliferation were localized to the site of application of
SPER/NO and were not associated with any changes in platelet aggregation or bleeding time.
Neither SPER nor polymer alone had any significant effects on any of the variables examined.
CONCLUSIONS Polymeric-based perivascular delivery of a NO donor produces a marked localized inhibition
of neointimal proliferation in balloon-injured arteries. This phenomenon is associated with
suppression of NF-kappaB activation and elevation of the vascular cGMP at the site of injury.
(J Am Coll Cardiol 2000;35:493–501) © 2000 by the American College of Cardiology
Restenosis, which occurs in 30% to 50% of patients within
three to six months, limits the long-term revascularization
benefits of coronary angioplasty and other transcatheter
interventions (1). Several potent agents that are directed
against one or more of the cellular events involved in
restenosis have failed to yield any demonstrable clinical
benefit (1). Crucial issues that may play a role include the
selection of agent(s) and the mode of drug delivery.
Among the several agents that have been proposed to
inhibit luminal narrowing following vascular injury, nitric
oxide (NO) and its donors may be ideal candidates. Besides
its vasorelaxant properties, NO is a potent inhibitor of
platelet activation (2), thrombosis (3), vascular smooth
muscle cell (VSMC) proliferation (4,5) and migration (6)
and extracellular matrix synthesis (7), all key events that
contribute to the luminal narrowing following vascular
injury. Several recent studies have demonstrated that NO
and NO-generating compounds reduce neointimal hyper-
plasia in experimental models of vascular injury (8–11).
There are, however, limitations associated with the systemic
administration of NO donors. First, NO is rapidly inacti-
vated by hemoglobin in the circulating blood resulting in
limited bioavailability. Second, the adverse systemic hemo-
dynamic and hemostatic effects often preclude administra-
tion of biologically effective doses of NO.
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To overcome these potential limitations, we used a
polymeric-based delivery system to examine whether
perivascular local treatment with spermine/nitric oxide
(SPER/NO), a NO-releasing diazeniumdiolate, inhibits
vascular injury-induced neointimal thickening in a balloon
ileofemoral artery injury model in rats. The rationale of this
approach was based on the enhanced delivery efficiency,
prolonged residence time and minimization of systemic side
effects with this local drug delivery approach. Recent find-
ings in several animal preparations have corroborated the
effective inhibition of luminal narrowing following vascular
injury with polymer-based perivascular delivery of antipro-
liferative agents (11–14). A secondary goal of this study was
to determine whether the inhibitory effects of NO on the
vascular proliferative response to injury may involve the
pleiotropic transcription factor, nuclear factor-kappaB (NF-
kappaB), an important modulator of genes involved in the
immune and proinflammatory response.
METHODS
Experimental design. All animal experiments were per-
formed according to the animal welfare policy of the
American Heart Association and after obtaining approval
from the institutional animal care committee. The experi-
mental design is illustrated in Figure 1.
Arterial injury model. Adult male Sprague-Dawley rats
weighing 400 to 500 g were anesthetized with pentobarbital
inhalation, and the ileofemoral arteries on both sides were
surgically exposed up to the first major branch of the
femoral artery. A 2F Fogarty balloon catheter (Baxter,
Deerfield, Illinois) was introduced from the left carotid
artery into the ileofemoral arteries. The balloon was inflated
with saline and gently withdrawn to the level of the
bifurcation of the aorta. The balloon was deflated and the
balloon-induced injury repeated for a total of three times
(15). After withdrawal of the catheter, the surgical incision
was closed, and the rats were allowed to recover from
anesthesia.
Perivascular delivery of NO donor. A local perivascular
delivery system composed of a biodegradable biocompatible
Abbreviations and Acronyms
cGMP 5 cyclic guanosine monophosphate
EEL 5 external elastic lamina
EMSA 5 electrophoretic mobility shift assay
IEL 5 internal elastic lamina
NF-kappaB 5 nuclear factor-kappaB
NO 5 nitric oxide
PCNA 5 proliferating cell nuclear antigen
SPER 5 spermine
SPER/NO 5 spermine/nitric oxide
VSMC 5 vascular smooth muscle cell
Figure 1. Figure illustrating the experimental design. The study consisted of four separate protocols. In study protocol 1, the effect of NO
donor on neointimal thickening was evaluated by histomorphometry at day 14 after balloon injury (n 5 28). In study protocol 2, PCNA
immunohistochemistry was used to assess DNA synthesis and VSMC proliferation at day 3 after balloon injury (n 5 18). Vascular cGMP
levels were also measured by radioimmunoassay in protocol 2 (n 5 11). In study protocol 3, activation of NF-kappaB, was examined by
EMSA and supershift assays at 6 hours after balloon injury (n 5 27). Platelet aggregation and bleeding time were also evaluated in some
rats in protocols 2 (n 5 6) and 3 (n 5 5). In study protocol 4, the in vitro release profile of NO form the polymeric delivery system was
examined in isolated arteries (n 5 3). cGMP 5 cyclic guanosine monophosphate; EMSA 5 electrophoretic mobility shift assay;
NF-kappaB 5 nuclear factor kappa B; PCNA 5 proliferating cell nuclear antigen; SPER/NO 5 spermine/NO (NO donor); SPER 5
spermine (vehicle for the NO donor); VSMC 5 vascular smooth muscle cells.
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polymeric material, atrigel, (Atrix Laboratories, Ft. Collins,
Colorado), a copolymer of polylactic and polyglycolic acid,
was used for the delivery of NO. The gel compound used in
the study has a unique reverse-phase gelation property. It
exists as a free-flowing liquid below body temperature and
solidifies into a viscous mass upon contact with perivascular
tissue fluid at body temperature (16). Thus, the polymer gel
enables a depot drug delivery in which the NO donor is
released over several days as it biodegrades, with complete
resorption in about 14 days (16). The NO-releasing diaze-
niumdiolate used in this study, SPER/NO, releases free NO
in a pH-dependent fashion with rapid release at acid pH.
Because the copolymer generates small amounts of acid
(D-lactic/L-lactic and glycolic acid) by hydrolytic cleavage
of their ester linkages during its degradation, magnesium
hydroxide (2.5% w/w) was added to the mixture to neutral-
ize the acid pH, thereby enabling controlled release of NO.
Immediately following arterial injury, a mixture of 2.5%
w/w of SPER/NO (5 mg), 2.5% w/w of magnesium
hydroxide (5 mg) and 200 mg of copolymer (0.2 ml) was
applied around the distal half of the injured arteries on one
side (injury 1 polymer 1 SPER/NO). A mixture of
spermine (SPER), the carrier vehicle for the NO donor, and
the copolymer was applied to the contralateral injured artery
(injury 1 polymer 1 SPER) in the first group of rats. In the
second group, the artery on one side was injured without any
treatment (injury, no treatment), while the other artery was
left uninjured without any treatment (no injury, no treat-
ment). The third group had the polymer alone applied
around the injured artery on one side (injury 1 polymer)
while the contralateral uninjured artery was treated with the
NO donor/polymer mixture (no injury 1 polymer 1
SPER/NO).
Histomorphometry. At 14 days after balloon injury, the
rats were killed by an intraperitoneal injection of sodium
pentobarbital, and the arteries were perfusion-fixed with 1%
glutaraldehyde, harvested and then immersion-fixed in 3%
glutaraldehyde. The tissue was processed routinely through
graded alcohols, cleared in xylene, paraffin-embedded, sec-
tioned (6 mm) and subsequently processed for light micros-
copy (hematoxylin/eosin). Cross-sectional area within the
external elastic lamina (EEL), the internal elastic lamina
(IEL) and the luminal area were determined by computer-
ized morphometry using an image analysis software (Opti-
mas 5.1, Bothell, Washington), and the intimal area (IEL-
luminal area) and medial area (EEL-IEL) were calculated.
Data were expressed as an average of three sections per each
arterial segment. Two independent investigators blinded to
the experimental group performed morphometric analysis.
PCNA immunohistochemistry. Proliferating cell nuclear
antigen (PCNA), a marker of proliferation, was measured
by immunocytochemistry in prepared sections for determi-
nation of VSMC proliferation that peaks at three days after
injury in this model. A commercially available PCNA
detection kit (Dako, Carpenteria, California) using a mouse
monoclonal antibody against PCNA was used with appro-
priate positive and negative controls, as described previously
(15). Data were presented as PCNA-positive cells/section
averaged over three sections per segment.
Electrophoretic mobility shift assay (EMSA). The har-
vested arteries were collected in ice-cold 0.9% saline and
then stripped of adventitia and frozen in liquid nitrogen
until nuclear extraction. For optimum extraction and anal-
ysis of NF-kappaB, 400 to 500 mg of tissue (derived from
approximately six arterial segments) was required. Thus,
arterial segments obtained from one limb of each six rats
(both arteries in the case of three rats that did not undergo
injury) were pooled. A total of 27 rats were studied for
NF-kappaB analysis by electrophoretic mobility shift assay
(EMSA). Nuclear extracts were prepared and their protein
concentrations were determined as described previously
(15). We assessed NF-kappaB binding at 6 h after injury
because we had previously shown it to peak at 6 h in this
model of arterial injury with decreased binding observed at
1 and 3 days (15).
For EMSA, nuclear extracts (6 mg) were incubated with
[32P]-labeled NF-kappaB oligonucleotide (100,000 cpm,
Promega, Madison, Wisconsin) in a buffer containing
0.25 mg/ml of poly (dI.dC) (Roche Molecular Biochemi-
cals, Indianapolis, Indiana), 50 mM Tris-HCl (pH 7.5),
250 mM NaCl, 5 mM MgCl2, 2.5 mM DTT, 2.5 mM
EDTA and 20% glycerol (total volume of 30 ml) for 30 min
at room temperature. Specificity was determined by the
addition of 100-fold excess unlabeled oligonucleotide as
competitor. For supershift assay, 15 ml of the antibodies
against p50 and p65 subunits of NF-kappaB (Santa Cruz
Biotechnology, Santa Cruz, California) were used. Reaction
was stopped by the addition of the loading buffer (250 mM
Tris-HCl, pH 7.5, 0.2% bromphenol blue, 0.2% xylene
cyanol, 40% glycerol). The DNA-protein complexes were
separated on a 4% polyacrylamide gel in a low strength
buffer (22.3 mM Tris, 22.3 mM borate, 0.5 mM EDTA) at
4°C. Gels were visualized by autoradiography. Quantitative
results of the assays were obtained by densitometry of
autoradiography.
Vessel cGMP assay. Arterial segments were harvested at
day 3, stripped of adventitia and the drug/copolymer mix-
ture, incubated with 10 mM 3-isobutyl-1-methylxanthine
for 1 min, and then immersed in 1 ml of ice-cold 10%
trichloroacetic acid followed by sonication (Heat Systems
Ultrasonics, Inc., Plainview, New York). Samples were then
centrifuged at 10,000 g for 15 min, and the aqueous phase
was frozen in liquid nitrogen and stored at 270°C before
assay. Each sample was thawed, trichloroacetic acid in the
supernatant was extracted by four washes with water-
saturated ether, and the sample was evaporated to dryness in
a Speed-vac. The sample was reconstituted in buffer and
assayed using commercially available radioimmunoassay kits
(Amersham, Arlington Heights, Illinois). Protein concen-
tration was determined by Coomassie Plus Assay (Pierce,
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Rockford, Illinois). Results were expressed as pmol of cyclic
guanosine monophosphate (cGMP)/mg protein.
Platelet aggregation and bleeding time. Platelet aggrega-
tion was assessed in whole blood by impedance aggregom-
etry pre-and 6 h (NF-kappaB group, n 5 5) and 3 days
(PCNA group, n 5 6) posttreatment with the NO donor
(3). Blood (0.5 ml) was collected in tubes containing sodium
citrate (0.3%), and aggregation was induced by 5 mg/ml of
collagen and quantified as rate of increase in impedance
(ohms/min) and maximum increase in impedance
(ohmsmax). Bleeding time was performed in anesthetized
rats by the tail transection method in five control rats and in
treated rats at 6 h (NF-kappaB group, n 5 5) and 3 days
(PCNA group, n 5 6) posttreatment with the NO donor.
Bleeding was induced by transection of the tail 5 mm from
the tip. The tails were gently blotted with the filter paper,
and the time in seconds to cessation of bleeding was
measured (17).
Release kinetics of NO. The NO release profile from the
polymeric-based perivascular delivery system was estimated
in perfused arterial segments in vitro using the acid-reflux
chemiluminescence protocol (10). Briefly, a 2 cm-long
segment of ileofemoral artery was harvested from a rat,
mounted in an organ chamber without removing the ad-
ventitia and perfused intraluminally and extraluminally with
phosphate buffer maintained at pH 7.4 and 37°C. A mixture
of 2.5% w/w of SPER/NO (5 mg), 2.5% w/w of magnesium
hydroxide (5 mg) and 200 mg of copolymer (0.2 ml) was
applied around the artery. A Whatman #50 (Whatman Inc.,
Clifton, New Jersey) filter paper was placed around the
gel-coated artery to wrap the polymer around the artery.
The polymer gelled immediately upon contact with the
artery. The perfusate from the artery was collected at
baseline and at 15-min intervals for the first 3 h and then
every 4 h until 12 h. Nitric oxide and its oxidation product
NO2
2 (NOx) were measured by chemiluminescence detec-
tor (model 2107, Dasibi, Glendale, California) after sample
reduction in boiling acidic vanadium chloride and reaction
with ozone at 98°C. Signals from the detector were analyzed
by a computerized integrator and recorded as areas under
the curve. Standard curves for the NO2
2 were linear over
Figure 2. Photomicrographs demonstrating the effects on balloon
injury-induced neointimal thickening. EEL 5 external elastic
lamina; IEL 5 internal elastic lamina; NO 5 nitric oxide;
spermine/NO 5 NO donor; spermine 5 vehicle for the NO
donor. (Hematoxylin & eosin; 3 100, reduced by 70%.)
Figure 3 (A and B). Bar graphs demonstrating the effects on
histomorphometric parameters. In the first group of rats, the
injured arteries on one side were treated with the NO donor-
polymer mixture (injury 1 polymer 1 spermine/NO) and a
mixture of spermine, the carrier vehicle for the NO donor, and the
polymer was applied to the contralateral injured artery (injury 1
polymer 1 spermine). In the second group, the artery on one side
was injured without any treatment (injury, no treatment) while the
other artery was left uninjured without any treatment (no injury,
no treatment). The third group had the polymer alone applied
around the injured artery on one side (injury 1 polymer) while the
contralateral uninjured artery was treated with the NO donor/
polymer mixture (no injury 1 polymer 1 spermine/NO). Data are
mean 6 SEM: n 5 number of animals. P values are based on
analysis of variance with Tukey’s multiple-comparison test except
for A where: * is p , 0.05 vs. injury 1 polymer 1 spermine based
on planned single-pair comparison. NO 5 nitric oxide. Open
box 5 no injury, no treatment (n 5 8); solid box 5 injury, no
treatment (n 5 8); gray box 5 injury plus polymer (n 5 6); slanted
line box 5 injury plus polymer plus spermine (n 5 14); dotted
box 5 injury plus polymer plus spermine/NO (n 5 14).
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the range of 1 nmol to 1 mmol. All sample concentrations of
NOx fell within this range.
Statistical analysis. Data are presented as mean 6 SEM.
The statistical difference between means was determined by
single-factor analysis of variance. A planned single-pair
comparison comparing SPER/copolymer versus SPER/NO
in injured vessels was performed initially. In addition,
Tukey’s multiple-comparison test was also performed to
examine differences across the various experimental groups
(GraphPad Prism 2.1). Probability values of p , 0.05 were
considered significant. The p values presented are based on
Tukey’s multiple-comparison test unless specified other-
wise.
RESULTS
A total of 94 rats were studied. There were four postpro-
cedural deaths but no bleeding complications. No signifi-
cant inflammatory response or abscess formation was ob-
served with the use of the copolymer. The biodegradable gel
was completely absorbed by 14 days in most animals in
protocol 1.
Histomorphometry. Illustrative photomicrographs of his-
tologic cross sections of ileofemoral arteries at the site of
application of the NO donor (distal injured segments) are
shown in Figure 2, and the results from the quantitative
morphometric analysis are shown in Figure 3. Balloon
injury of vessels resulted in the development of significant
neointimal thickening, which was not affected by treatment
with either copolymer alone or the SPER/copolymer mix-
ture. Quantitative analysis revealed that SPER/NO mark-
edly reduced the intimal area (p , 0.05 to p , 0.01) and the
intima to media (I/M) ratio (p , 0.005) by about 75%,
whereas the medial areas and the areas within the EEL did
not differ between the groups. The significant lumen pres-
ervation associated with SPER/NO- compared with SPER/
copolymer-treated vessels (p , 0.05 for planned single-pair
comparisons) was primarily due to the reduction in the
intimal area since the vessel size (area within the EEL) did
not change (Fig. 3A).
Morphometric analysis of segments proximal to the site
of application of the NO donor (segment A and B) revealed
no significant effects of the NO donor on the intimal area or
the I/M ratio (Table 1). Thus, these data show that the
marked suppression of neointimal proliferation by the NO
donor was localized to the site of application of the drug.
PCNA immunohistochemistry. The quantitative analysis
shown in Figure 4 revealed that vascular injury resulted in a
significant increase in PCNA-positive cells, compared with
the uninjured control arteries. Treatment with SPER/NO,
but not SPER alone, produced pronounced inhibition
(.75%, p , 0.005) in PCNA-positive cells in both injured
as well as uninjured arteries.
NF-kappaB activation. As shown in Figure 5, baseline
nuclear binding of NF-kappaB was present in the EMSA of
nuclear extracts from control, uninjured arteries. This is
consistent with the constitutive expression of NF-kappaB in
VSMC in vitro (18). The NF-kappaB binding was confined
to the media since the injured arteries were completely
devoid of endothelium (Evans Blue stain, data not shown)
Figure 4. Bar graphs demonstrating the effects on cell proliferation
as assessed by PCNA immunohistochemistry. Data (mean 6
SEM) are expressed as the number of PCNA-positive cells per
section averaged over three sections per artery. N 5 6 in each
group. *p , 0.005 vs. no treatment or polymer 1 spermine.
PCNA 5 proliferating cell nuclear antigen. Open box 5 no injury;
solid box 5 injury.
Table 1. Effect of Spermine/NO on Histomorphometric Parameters
Area (mm2)
Proximal Site (Segments A, B) Treatment Site (Segments C, D)
Control Treatment Control Treatment
EEL 0.428 6 0.021 0.387 6 0.022 0.312 6 0.019 0.322 6 0.025
Lumen 0.223 6 0.020 0.198 6 0.012 0.166 6 0.019 0.213 6 0.009*
Media 0.161 6 0.021 0.154 6 0.019 0.108 6 0.005 0.096 6 0.019
Intima 0.039 6 0.009 0.043 6 0.013 0.035 6 0.006 0.011 6 0.009**
Intima: Media 0.242 6 0.016 0.274 6 0.011 0.330 6 0.057 0.089 6 0.062**
Values are mean 6 SEM in 14 rats. The arteries were injured by balloon denudation, harvested at day 14 and serially cut into 4 segments (A–D) from the bifurcation of the
aorta to immediately proximal to the first major branch of the femoral artery. Morphometric analysis of sections proximal to the site of application of the NO donor (segments
A and B) are compared with those at the site of application of the NO donor (segments C and D).
Control group 5 spermine 1 polymer; treatment group 5 spermine/NO 1 polymer. EEL 5 external elastic lamina; NO 5 nitric oxide.
*p , 0.05; **p , 0.005 vs. control.
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and the adventitia was completely stripped off. The NF-
kappaB nuclear binding in the EMSA of nuclear extracts of
uninjured arteries was significantly inhibited by SPER/NO
by 38 6 9% compared with control (p , 0.01), but not by
SPER (14 6 7%). Balloon injury produced a marked
increase in nuclear binding of NF-kappaB (157 6 36%
compared with no injury), which was markedly inhibited by
SPER/NO (61 6 14%, p , 0.005).
The incubation of nuclear extracts with p50 and p65
antibodies reduced nuclear binding and was also associated
with mobility retardation (Fig. 5), thus demonstrating the
specificity of bands detected in the EMSA.
Vessel cGMP. Vascular cGMP levels were significantly
elevated after treatment with the SPER/NO compared with
SPER alone in both injured and uninjured arteries (Fig. 6),
demonstrating a direct effect of the NO donor on VSMC
(since adventitia was removed).
Platelet aggregation and bleeding time. The effect of NO
donor on platelet aggregation is shown in Table 2. Sperm-
ine/nitric oxide had no significant inhibitory effects on
platelet aggregation. The bleeding time did not differ
significantly between control rats (211 6 23 seconds) and
the treated rats at either 6 h (234 6 34 s) or 3 days (213 6
20 s) following treatment with the NO donor.
In vitro NO release. Covering the artery with spermine/
NO-copolymer mixture elicited very little NO signal, but
this increased markedly with the addition of buffer outside
the filter paper cylinder. This indicates that elution of NO
from the gel is critically dependent on the aqueous environ-
ment maintained at pH 7.4 and 37°C. Graphical integration
of the data indicated that the NO release peaked at 40 min
(4.5 6 0.5 mmol) with approximately 95% of total NO
release occurring in the first 150 min, and minute quantities
still being detectable at 12 h. This is in agreement with the
NO release half-life from SPER/NO of about 40 min (19).
There was no detectable signal in the perfusate from arteries
covered with SPER-copolymer mixture.
DISCUSSION
In this study, we have demonstrated that polymeric-based
perivascular delivery of an NO donor produces a marked
inhibition of neointimal proliferation in balloon-injured
arteries. This phenomenon is associated with suppression of
NF-kappaB activation and elevation of the vascular cGMP
at the site of injury. Moreover, the inhibitory effect of the
NO donor on neointimal proliferation is confined to the site
of application, thereby demonstrating a local effect of NO
delivery. Although inhibition of neointimal proliferation by
NO or NO donors has been observed previously (8–10,20),
the findings in this study are novel in two respects. First,
this is the first report of inhibiting neointimal proliferation
using the novel local polymeric-based perivascular delivery
of NO. Second, the inhibitory effect of NO on balloon
injury–induced NF-kappaB activation has not been re-
ported previously in vivo.
NO donor. Spermine/nitric oxide is one of several new
NO-releasing diazeniumdiolates (compounds containing
the [N (O) NO]-functional group, formerly called
‘NONOates’) (19) that exhibit potent vasorelaxant (21),
Figure 5. Electrophoretic mobility shift assays demonstrating the effects of NO donor, spermine/NO, on NF-kappaB DNA binding
activity (representative of three similar experiments). Supershifted immunoreactive band using antibodies against the p50 and p65 subunits
of NF-kappaB are indicated by the arrows. NF-kappaB 5 nuclear factor kappa B; NO 5 nitric oxide; Spermine 5 the carrier vehicle for
the NO donor.
Figure 6. Bar graphs demonstrating the effects on vascular cGMP
levels in rats with no treatment (n 5 3), rats treated with
polymer 1 spermine/NO (n 5 5) and polymer 1 spermine (n 5
3). Data are mean 6 SEM. *p , 0.01 vs. no treatment or
polymer 1 spermine. cGMP 5 cyclic guanosine monophosphate.
Open box 5 no injury; solid box 5 injury.
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antiplatelet (3) and antimitogenic effects (5) in vitro and in
animal models. The NO-releasing diazeniumdiolates re-
lease free NO in a pH-dependent fashion with predictable
first-order kinetics. Their biological half-lives range from
2 s to several days (19); they exhibit greater potency (19),
and, thus, they may offer a better therapeutic potential as
antiatherogenic agents compared with the conventional NO
donors such as nitrates and nitroprusside.
Effects of NO on NF-kappaB. The transcription factor,
NF-kappaB, plays an important role in the transcription of
a variety of genes, primarily the ones involved in the
immune and proinflammatory response (22,23). Nuclear
factor-kappaB has been shown to be involved in the
cytokine-induced expression of adhesion molecules and
monocyte-colony stimulating factor in endothelial cell cul-
tures (22,23), and, in a rat balloon injury model, we recently
demonstrated the involvement of NF-kappaB pathway in
VSMC proliferation and neointimal hyperplasia in injured
arteries (15). In this study, we have confirmed our previous
observation of increased vascular NF-kappaB activity in-
duced by injury. The potential mechanism of this effect may
be an increase in the oxidant stress or a cytokine induced by
mechanical injury, which may trigger the degradation of
IkappaBalpha (22–25) with consequent dissociation, nu-
clear translocation and DNA binding of p50 and p65
subunits of NF-kappaB (as supported by the EMSA data).
The finding that NO inhibits NF-kappaB activity is gen-
erally in agreement with observations from previous in vitro
studies (24–26). However, the new finding in this study is
that NO suppresses NF-kappaB activity in injured vessels in
vivo. The exact mechanisms by which NO inhibits NF-
kappaB activity in vivo is beyond the scope of this study.
However, previous studies in vitro suggest that NO may
reduce proteolytic degradation of the stabilizing subunit,
IkappaBalpha, either via a direct dephosphorylating effect or
indirectly via its antioxidant effect (24–26).
There are several noteworthy features of this study. First,
a relatively short (,3-h) arterial-wall exposure to the NO
donor (based on the NO release studies in vitro) resulted in
a prolonged (2-weeks) biologic effect, with the NO donor-
treated arteries demonstrating little neointimal formation.
Certain molecular events initiated during this critical time
period may be essential for vascular lesion formation. Thus,
interventions such as NO that inhibit these acute-phase
events (including NF-kappaB activation) may suppress
downstream events in the response-to-injury cascade result-
ing in sustained biologic effects. An alternative explanation
is that the measured NOx activity in vitro is likely under-
estimating the duration of action of the NO donor/polymer
mixture in vivo as evidenced by increased cGMP levels at
day 3. Second, the effect of NO delivery was remarkably
local. While the entire length of the ileofemoral artery was
ballooned during the study, the gel containing NO donor
was applied only to the distal part of the artery, and it was
only this arterial segment that showed suppression of
neointimal proliferation. The lack of effects of the NO
donor on neointimal proliferation in the contralateral in-
jured artery treated with the vehicle, SPER, alone is
consistent with the local effect of the NO donor and
excludes the involvement of a systemic pathway. Third,
periadventitial delivery of NO effectively inhibited vascular
lesion formation after endoluminal balloon-denudation in-
jury of rat ileofemoral arteries. The intraluminal concentra-
tion of NO delivered by this route was in the range (4 mM)
that exhibits antiproliferative effects on VSMC in vitro
(4,5). The medial concentration of NO would be expected
to be higher than the luminal concentration and therefore
inhibit medial SMC proliferation more markedly. It is
possible that NO acted directly on the medial SMC, and the
adventitia was simply a convenient route of administration.
However, based on the emerging data regarding the direct
role of adventitial cells in neointimal formation, it is likely
that inhibition of these cells by periadventitial delivery of
NO and other potent antiproliferative agents may offer a
more effective therapeutic strategy. Fourth, the inhibitory
effect of NO on neointima formation appeared to be equal
in magnitude to that observed on DNA synthesis. This
indicates that the antiproliferative effects of NO might
primarily contribute to its inhibitory effects on neointima
formation. However, this study does not address the effect
of NO on VSMC migration. We, therefore, cannot com-
pletely exclude the role of NO’s known antimigratory effects
(6) in this study. Fifth, the lack of effects on platelet
aggregation and bleeding time excludes the possibility that
perivascularly delivered NO suppressed neointimal prolifer-
ation by altering systemic platelet and coagulation function.
However, since platelet adhesion on the injured arterial
surface is important in the proliferative response to injury, it
is likely that inhibition of local platelet deposition by the
NO donor may have contributed to suppression of neoin-
timal hyperplasia in this study. Sixth, the polymer used in
this study was noted to induce a severe inflammatory
Table 2. Platelet Aggregation Responses
Ohms/Min Ohmsmax
Pre-Rx Post-Rx Pre-Rx Post-Rx
6 h (n 5 5) 4.0 6 0.3 3.4 6 0.5 11.8 6 1.1 10.5 6 2.2
3 days (n 5 6) 4.5 6 0.5 3.9 6 0.4 13.3 6 0.9 12.1 6 1.6
Values are mean 6 SEM. Platelet aggregation responses were measured in citrated arterial blood pre- and 6 h and 3 days
posttreatment with spermine/NO as described in the Methods section. All P 5 ns (Student paired t test).
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reaction in previous studies in rabbits (27) and swine (28)
but not in rats (13). We did not see a significant inflam-
matory response in our rats treated with the polymer. Likely
explanations for the differences include the particle size of
the polymer, systemic versus perivascular administration and
species variability. The biocompatibility of the polymer is
further supported by the lack of incremental neointimal
formation.
Study limitations. There are several limitation of this
study. Although the rat artery balloon injury model is not an
optimal model of human disease, and extravascular delivery
of drugs is not yet generally feasible, this study provides
“proof of concept” evidence that perivascularly delivered
NO may be important in inhibiting neointimal hyperplasia.
The precise role of NO and its modulation of NF-kappaB
activation on the vascular proliferative response to injury is
not clear. These studies are extremely difficult to accomplish
in vivo. However, we and others have recently demonstrated
in studies in vitro that the inhibitory effects of NO on
VSMC proliferation (25,29) and endothelial cell activation
(24) involve the NF-kappaB pathway. The release kinetic
profile for NO from perivascularly administered NO donor-
copolymer mixture was evaluated in an in vitro model.
Drugs can be cleared from the perivascular space by 1)
transmural diffusion, 2) absorption by extraarterial mi-
crovessels, and 3) absorption by lymphatics (30). The in
vitro model obviously precludes identification of such mech-
anisms by which NO is cleared from the perivascular space
and enters vascular tissue.
Implications. Recent studies in experimental models and
in humans indicate that NO and NO-generating com-
pounds possess potent vasorelaxant (2), antiplatelet (2,3)
and antiproliferative properties (4,5,8–11). These observa-
tions have important implications for these compounds as
effective therapeutic agents for treatment of vasculoprolif-
erative states such as restenosis after coronary interventions.
However, rapid inactivation by hemoglobin in the circulat-
ing blood, thereby limiting high target concentration of NO
for optimal biologic effects, and adverse hemodynamic
effects preclude systemic administration of NO donors.
Furthermore, low efficiency and rapid redistribution of the
infused material have limited local endovascular delivery of
therapeutic agents to modulate the vasculoproliferative re-
sponse to injury. In this study a local perivascular delivery
was carried out by placing an NO donor–containing poly-
mer in close proximity with the vessel wall, ensuring a high
local concentration of NO and minimizing blood flow
washout and rapid inactivation of NO. Such a delivery
system may also offer the advantage of dissociating the
desired local antiplatelet and antiproliferative effects from
undesired adverse systemic hemodynamic and hemostatic
effects. We are currently adopting a similar perivascular
strategy in a porcine model using intrapericardial delivery of
therapeutic agents via a percutaneous subxyphoid approach
to modulate the coronary arterial response to injury.
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